Baidu
map

BMC Urol:亚洲前列腺癌双周、减少剂量多烯紫杉醇的回顾可行性研究

2017-09-03 AlexYang MedSci原创

最近,有研究人员评估了在韩国患有去势难治性前列腺癌(CRPC)病人中,多烯紫杉醇减少剂量和双周频次化疗的临床结果。研究人员回顾性的评估了48名患有转移CRPC病人的医疗记录,这些病人接受过两周一次频率(在第1天静脉注射多烯紫杉醇40mg/m2,另加每日两次的5mg氢化波尼松),时间为2012年到2015年,地点在三星医疗中心(韩城,韩国)。在2013年10月进行双周次频率之前,24名患有CRPC病

最近,有研究人员评估了在韩国患有去势难治性前列腺癌(CRPC)病人中,多烯紫杉醇减少剂量和双周频次化疗的临床结果。研究人员回顾性的评估了48名患有转移CRPC病人的医疗记录,这些病人接受过两周一次频率(在第1天静脉注射多烯紫杉醇40mg/m2,另加每日两次的5mg氢化波尼松),时间为2012年到2015年,地点在三星医疗中心(韩城,韩国)。在2013年10月进行双周次频率之前,24名患有CRPC病人的标准化疗为每3周75mg/m2多烯紫杉醇。在2013年10月后,24名化疗病人接受每2周40 mg/m2多烯紫杉醇剂量。

研究发现,病人在两种治疗小组中的基线特性是相似的。治疗中止最常见的起因为疾病恶化,在3周次治疗小组中出现17名(71%)病人,在双周次治疗小组中出现了20名(75%)病人。另外,在3周次治疗小组和双周次治疗小组中PSA响应分别为12名(50%)病人和11名(46%)病人(p=0.683)。治疗失败时间(TTTF, 4.5 vs 3.9月 )和恶化时间(TTP, 5.0 vs 4.2月)在3周次治疗小组和双周次治疗小组中差异并不显著。最后,研究人员指出,在该回顾性研究范围中,双周次减少剂量多烯紫杉醇在治疗韩国转移CRPC病人中是有作用的且具有良好的耐受性。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1974761, encodeId=c11919e47618a, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Nov 02 07:14:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022909, encodeId=5718202290976, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Wed Oct 11 05:14:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417352, encodeId=5571141e35250, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Tue Sep 05 06:14:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240490, encodeId=ebbe2404908d, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Sep 04 22:05:19 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240203, encodeId=72e5240203d0, content=学习啦!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Mon Sep 04 06:06:30 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240152, encodeId=e0ca24015215, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sun Sep 03 23:24:41 CST 2017, time=2017-09-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1974761, encodeId=c11919e47618a, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Nov 02 07:14:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022909, encodeId=5718202290976, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Wed Oct 11 05:14:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417352, encodeId=5571141e35250, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Tue Sep 05 06:14:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240490, encodeId=ebbe2404908d, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Sep 04 22:05:19 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240203, encodeId=72e5240203d0, content=学习啦!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Mon Sep 04 06:06:30 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240152, encodeId=e0ca24015215, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sun Sep 03 23:24:41 CST 2017, time=2017-09-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1974761, encodeId=c11919e47618a, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Nov 02 07:14:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022909, encodeId=5718202290976, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Wed Oct 11 05:14:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417352, encodeId=5571141e35250, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Tue Sep 05 06:14:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240490, encodeId=ebbe2404908d, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Sep 04 22:05:19 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240203, encodeId=72e5240203d0, content=学习啦!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Mon Sep 04 06:06:30 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240152, encodeId=e0ca24015215, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sun Sep 03 23:24:41 CST 2017, time=2017-09-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1974761, encodeId=c11919e47618a, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Nov 02 07:14:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022909, encodeId=5718202290976, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Wed Oct 11 05:14:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417352, encodeId=5571141e35250, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Tue Sep 05 06:14:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240490, encodeId=ebbe2404908d, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Sep 04 22:05:19 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240203, encodeId=72e5240203d0, content=学习啦!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Mon Sep 04 06:06:30 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240152, encodeId=e0ca24015215, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sun Sep 03 23:24:41 CST 2017, time=2017-09-03, status=1, ipAttribution=)]
    2017-09-04 changjiu

    学习了.谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1974761, encodeId=c11919e47618a, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Nov 02 07:14:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022909, encodeId=5718202290976, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Wed Oct 11 05:14:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417352, encodeId=5571141e35250, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Tue Sep 05 06:14:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240490, encodeId=ebbe2404908d, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Sep 04 22:05:19 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240203, encodeId=72e5240203d0, content=学习啦!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Mon Sep 04 06:06:30 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240152, encodeId=e0ca24015215, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sun Sep 03 23:24:41 CST 2017, time=2017-09-03, status=1, ipAttribution=)]
    2017-09-04 tanxingdoctor

    学习啦!谢谢分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1974761, encodeId=c11919e47618a, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Nov 02 07:14:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022909, encodeId=5718202290976, content=<a href='/topic/show?id=db3b3852004' target=_blank style='color:#2F92EE;'>#可行性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38520, encryptionId=db3b3852004, topicName=可行性)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Wed Oct 11 05:14:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417352, encodeId=5571141e35250, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Tue Sep 05 06:14:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240490, encodeId=ebbe2404908d, content=学习了.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Mon Sep 04 22:05:19 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240203, encodeId=72e5240203d0, content=学习啦!谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLK1wzJZRTON4gxYUibhUyOypBwMibC4R7SsppicGhz5Ogoy0VVq4CWnqaD2Moeib8RWxI5lOiaVmnxpan/0, createdBy=c53f1730331, createdName=tanxingdoctor, createdTime=Mon Sep 04 06:06:30 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240152, encodeId=e0ca24015215, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=08bb2061153, createdName=189****7206, createdTime=Sun Sep 03 23:24:41 CST 2017, time=2017-09-03, status=1, ipAttribution=)]
    2017-09-03 189****7206

    学习了谢谢分享

    0

相关资讯

J Urol:MRI/US融合活检决定局部治疗的适用性

最近,有研究人员评估了局部治疗(FT)在接受多参数核磁共振成像(mpMRI)和靶向活检男性中的适用性,并且关联了根治性前列腺切除术后(RP)的全角组织学。研究对象选自于2010年到2016年靶标活检确定的前列腺癌(CaP)的454名男性,这些前列腺癌的鉴定来源于mpMRI中有病变的区域(ROI)。FT的适用性限制到ROIs中4+3最大的格林森得分,具有或者不具有其他的低风险CaP焦点(GS 3+3

Scand J Urol:他汀类药物使用与雄激素剥夺疗法治疗前列腺癌恶化的关系

在一些观察性的研究中,他汀类药物的使用与男性前列腺癌(PCa)恶化风险和死亡率的减少相关。最近,有研究人员调查了在PCa诊断时他汀类药物的使用与接受雄激素剥夺疗法(ADT)作为起始治疗手段的患有晚期或者转移性PCa男性的PCa恶化之间的关系。 研究群体包括了在2007年到2013年,在2个丹麦泌尿系机构中接受ADT作为起始治疗方法的所有男性病人。主要的结果为定义为去势难治性PCa或者

Nat Commun:前列腺癌中雄激素受体信号途径和PARP通路之间的合成致死作用

最近,来自英国剑桥大学癌症研究中心的一项研究表明,前列腺癌中雄激素受体信号途径和PARP通路之间具有合成致死作用。越来越多的数据阐释了同源重组(HR)在去势难治性前列腺癌中的缺陷,致使这些肿瘤对PARP抑制作用表现为敏感。最近,研究人员阐明了雄激素受体(AR)来维持HR基因的表达和在前列腺癌中HR活性的直接需求。研究发现,在雄激素阻断治疗(ADT)后,PARP调控的修复通路在前列腺癌中表达上调。更

Eur Urol:将勃起功能恢复的年龄差异考虑入根治性前列腺切除术的利弊。

尽管主动监测越来越多地应用于低危前列腺癌患者的管理中,但许多符合条件的患者仍然接受了手术治疗。患者考虑手术而不是主动监视的一个原因是存在这样一个论点:术后勃起功能的恢复可能性是年龄依赖性的,也就是说,延迟手术的患者可能失去手术后恢复勃起功能的机会。

Int J Cancer:前列腺癌 vs 乳腺癌的发病率和死亡率表明,前列腺癌正在被过度诊断

全球乳腺癌发病率自20世纪70年代末开始一直呈上升趋势。美国8名妇女一生中就会有1人患乳腺癌。中国不是乳腺癌的高发国家,但不宜乐观,近年我国乳腺癌发病率的增长速度却高出高发国家1~2个百分点。2012年我国肿瘤登记地区前列腺癌发病率为9.92/10万,列男性恶性肿瘤发病率的第6位。发病年龄在55岁前处于较低水平,55岁后逐渐升高,发病率随着年龄的增长而增长,高峰年龄是70~80岁。家族遗传型前列腺

Mol Cancer:研究揭示ZEB1-AS1在前列腺癌细胞增殖及转移中的机制

近期研究表明,长链非编码RNAs(lncRNAs)在肿瘤的发生和进展中起着重要的作用。LncRNA ZEB1义1(ZEB1-AS1)位于ZEB1基因的启动子区,目前对其表达的作用机制知之甚少。使用RACE来获得ZEB1-AS1的序列。采用RNA干扰技术减少ZEB1-AS1的表达。使用腺病毒表达载体增加ZEB1-AS1表达。使用CHIP 和RIP来检测ZEB1-AS1调节ZEB1的表观遗传机制。使用

Baidu
map
Baidu
map
Baidu
map